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INTRODUCTION
Patients with chronic lymphocytic
leukemia (CLL) assigned to stereotyped
subset #4 are characterized clinically by
an early age at diagnosis and an indolent
disease course and molecularly by B-cell
receptor immunoglobulins (BcR IGs) that
exhibit a series of distinctive immuno-
genetic features (1,2). More specifically,
they are IgG-switched (a rarity in CLL
since the great majority of CLL clones,
>90% of all cases, express IgM/IgD) and
are composed of heavy chains encoded
by the IGHV4-34 gene and light chains
encoded by the IGKV2-30 gene (3–5). The
antigen-binding sites of subset #4 are
equally interesting, being composed of a
variable heavy complementarity deter-
mining region 3 (VH CDR3) that is long
and enriched in positively charged
residues (reminiscent of pathogenic anti-
DNA antibodies) (3,4). Anti-DNA is the
most common specificity in autoreactiv-
ity, with DNA binding often acquired
through surface-active basic amino acids;
predominantly arginine (R) but also, to a
lesser extent, lysine (K) (6–8). This point
is worthy of note since the VH CDR3 of
subset #4 is defined by a (R/K)RYY motif
which is deemed to not only be “CLL-bi-
ased” but also exclusive to subset #4 as it
has never been found outside this con-
text (3,4). In addition, both the VH and
variable kappa (VK) domains of subset
#4 demonstrate a high impact of somatic
hypermutation (SHM) and are remark-
able for carrying shared (“stereotyped”)
SHM, that is, identical changes at the
same codon position of the variable do-
main (3,9).
Subset #4 is also outstanding due to in-
tense intraclonal diversification (ID)
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within their IG genes in the context of on-
going SHM, alluding to an active, ongo-
ing interaction with antigen(s) (10,11). In-
deed, by conducting a large-scale
longitudinal study of subset #4 we previ-
ously established: (i) the existence in most
cases of distinct “clusters” of subcloned
sequences; (ii) a hierarchical pattern of
subclonal evolution, thus revealing which
SHMs were negatively or positively se-
lected overtime; and, (iii) subclonal drift,
that is, temporal changes in the relative
size of different clusters of sequences (12).
Nevertheless, this study only investi-
gated clonal evolution at an individual
case level and hence could not shed light
on the clonal ancestry of subset #4 as a
whole, which is relevant since the re-
markable biological and clinical similari-
ties of subset #4 cases strongly support
derivation from a common ancestor. In
an attempt to trace the ontogeny of sub-
set #4, we here sought to revisit ID in
subset #4 and reconstruct their evolu-
tionary history by determining the struc-
ture of a community of related clones
profiled at different time points for both
IG heavy and light chains.
MATERIALS AND METHODS
Patient Group
Peripheral blood samples were col-
lected at multiple time points from eight
CLL patients meeting the International
Workshop on Chronic Lymphocytic
Leukaemia (iwCLL) criteria; these eight
patients, on the basis of both their IG
gene sequence features and our previ-
ously established criteria, were assigned
to subset #4 (1,3,4,13). Patients’ demo-
graphics and clinical and molecular data
are summarized in Supplemental Table 1.
Cases were analyzed over a six-year pe-
riod (range 7 to 72 months, median 20
months) and no patient received treat-
ment during sampling (Supplemental
Table 1). The diagnostic sample was
available, and called time point 1, for 6
of the 8 patients analyzed. No diagnostic
samples were available for the remaining
two patients (P0103 and P2451) and
therefore the initial sample (time point 1)
analyzed for these patients were 81 and
63 months post diagnosis, respectively.
Written informed consent was obtained
in accordance with the Declaration of
Helsinki and the study was approved by
the local ethics review committee.




PCR amplification using the high-
 fidelity Accuprime Pfx polymerase (In-
vitrogen [Thermo Fisher Scientific,
Waltham, MA, USA]), subcloning and se-
quence analysis and interpretation were
performed as described previously. The
sequence data evaluated herein has been
reported previously (1,3,9–12).
Visualization of Clonal Evolution in
Subcloned IG Gene Sequences
Sequence data was processed using the
Damerau-Levenshtein edit distance algo-
rithm (14–16). The Damerau-Levenshtein
distance, as defined in this paper, is a
multivariate function of two parameters;
in this study these two parameters are
the amino acid (or nucleotide) sequences.
The defined distance is used for the com-
putation of the difference between two
IG chains. It is a distance metric in the
sense that, given the amino acid (or nu-
cleotide) sequences s1, s2, s3, the follow-
ing conditions apply:
• Nonnegativity: d(s1, s2) ≥ 0;
• Nondegeneracy: d(s1, s2) = 0 if and
only if s1 = s2;
• Symmetry: d(s1, s2) = d(s2, s1);
• Triangle inequality: d(s1, s2) + d(s2, s3) ≥
d(s1, s3).
The analytical form of the Damerau-
Levenshtein distance between two
chains, a and b, having lengths M and N,
respectively, is defined by the following:
where lev is a two-dimension matrix with
M rows and N columns and the (i,j) entry
is leva,b(i,j), where i = 0, 1, 2, … , M-1 and 
j = 0, 1, 2, … , N-1. This matrix has one in
the element when a match is found be-
tween the i-th letter of the chain a and the
j-th element of chain b; otherwise this ele-
ment is equal to 0. Application of this al-
gorithm to the entire IG variable domain
was used to illustrate the diversity/
 similarity between subcloned sequences
obtained from different time points across
all patients. Consequently, each clonal se-
quence was compared with the entire
data set, i.e., all clonal sequences obtained
irrespective of time point or case, and this
strategy provided a more robust evolu-
tionary model for CLL subset #4 than in-
ferring clonal relations at an individual
case level. Modeling the genesis of subset
#4 in this manner facilitated the deconvo-
lution of sequence changes that occurred
during the life of the clone. The distance
matrix (17,18) resulting from the compari-
son process was used to interconnect each
clone to the remainder in a minimum
spanning tree which was subsequently vi-
sualized using purpose-built tools (19–21).
Clones were positioned within this tree
according to their individual distances,
thus forming clusters which illustrated
clonal relatedness beyond the individual
patient level.
To explore the functional similarities of
observed sequence changes, we followed
the ImMunoGeneTics information system
(IMGT) classification of the 20 common
amino acids for the properties of hy-
dropathy and chemical characteristics
(http://www.imgt.org/IMGTeducation/
Aide-memoire/_UK/aminoacids/) 
and performed the following compar-
isons: (i) amino acid sequence distance
including only replacement mutations;
(ii) amino acid sequence distance when
considering amino acids with similar
physicochemical properties as single
equivalent entities; (iii) amino acid se-
quence distance when considering amino
acids within the same hydropathy group
as single equivalent entities; and (iv) nu-
cleotide sequence distance.
Focusing on both the VH and VK
CDR3, hierarchical visualization was per-
formed and by determining which nu-
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cleotide or amino acid had the highest
probability of appearing at a certain posi-
tion, a hypothetical VH and VK CDR3 se-
quence from which all subset #4 CDR3
sequences derive could be constructed.
More specifically, a hierarchical tree struc-
ture comprised of nodes and branches
was assembled. Within this structure, the
root node corresponded to the derived
(proposed) ancestral sequence, and the
branches were determined based on the
calculated optimal string distance of each
node. The string distance of a node indi-
cated its position from the root node and
also its proximity to the other nodes.
RESULTS
Composite Clusters of Subset #4 IG
Sequences: Convergent Patterns of
Subclonal Evolution
Clustering at the amino acid level.
Analysis of the IGHV–IGHD–IGHJ
amino acid sequences produced six dis-
tinct clusters (Figure 1A). Four of these
clusters were composed of subclonal se-
quences obtained from different patients
(P0907, P1422, P3020 and P1939), with
each individualized cluster exhibiting a
distinctive dispersion of clones, thus re-
flecting the varying extent of ID among
subset #4 cases (Supplemental Figure 1).
The remaining two clusters largely con-
sisted of sequences from two patients
each (composite clusters). The first such
cluster contained sequences from pa-
tients P3916 and P2920 that grouped
closely together. The second multimem-
ber cluster primarily contained se-
quences from two patients, P0103 and
P2451; however, seven subcloned se-
quences from patient P1422, stemming
from two different time points also clus-
tered within this group, while the major-
ity of sequences from patient P1442 clus-
tered separately and at some distance
away (Figures 1A,B). Thus, subcloned se-
quences from individual subset #4 cases
clustered close together and behaved as
if they were clonally related, that is, as if
they stemmed from a community of
clones with common ancestry. The ob-
served branching may be indicative of
special selective pressures occurring in
parallel in distinct subclones.
Similar analysis of the IGKV–IGKJ
amino acid sequences produced five
clusters (Figure 1C). Two clusters were
located within a very close distance,
forming a more central core from which
a further two clusters emanated. More
specifically, the first cluster was formed
by two patients (P2920 and P0907), while
the second closely neighboring cluster
contained the subcloned sequences from
P0103 and P2451. Subcloned sequences
from P3916 bridged these two clusters
(Figure 1D). Clonal sequences from
P1422 formed one of the two more dis-
tant clusters, while the other cluster was
composed of clonal sequences from
P1939. Patient P3020, previously found
to carry limited ID despite bearing the
highest SHM load (within both the IG
heavy and light chain), was distanced
from all other clusters. As with the clus-
ter analysis of IG heavy chain sequences,
we noted that individual IG kappa se-
quences occasionally were separated
from their respective clusters and, in-
stead, attached to clusters generated by
other patients and located some distance
away. Hence, the pattern of clustering
evidenced from the kappa light chain se-
quences is analogous to that of their
partner heavy chains, thereby reenforcing
the idea that subset #4 essentially consti-
tutes a community of related clones that
follow closely similar ontogenetic and
evolutionary pathways.
Clustering based on shared amino
acid properties. Further comparisons
were performed at the amino acid level
by permitting a degree of ambiguity
through the use of amino acid equiva-
lences, that is, following the IMGT
grouping of amino acids into classes
based on distinct physicochemical or hy-
dropathic properties. Excluding amino
acids with the same physicochemical
properties from the sequence distance-
defining algorithm, that is, considering
such amino acids as equal and, hence,
not resulting in an overall change, re-
sulted in a slight alteration to cluster for-
mation. At the IG heavy chain level, five
distinct clusters were now observed as
opposed to the six clusters initially ob-
served when physicochemical properties
were included; this change primarily re-
sulted from the clustering of P3020 with
P0907 (previously occurring as two dis-
tinct clusters) (Figure 2A). For subset #4
kappa light chains, the effect on cluster
formation was very minor (Figure 2B).
When amino acids within the same hy-
dropathy groups were considered as
equal, it was noted that mutations intro-
duced by SHM did not lead to striking
changes in hydropathy for any patient.
Nevertheless, one difference observed
when clustering in this manner con-
cerned the subcloned IG heavy chain se-
quences of P3020 which, although re-
maining as a distinct cluster, now
emerged from the cluster produced by
patient P0907; prior to taking physico-
chemical properties or hydropathy into
consideration, this cluster hailed from the
central core cluster (Supplemental Fig-
ures 2, 3). The observed clustering based
on shared amino acid properties indicates
strong functional constraints for preser-
vation of critical physicochemical proper-
ties; the limited range of permissible
amino acids potentially reflects selection
events governed by structural constraints
for optimal antigen recognition.
Clustering at the nucleotide level. Fi-
nally, clustering based on changes within
IG heavy chain nucleotide sequences
produced an individual and distinct clus-
ter for six patients, while patients P0103
and P2451 remained clustered together
(Figure 3A). Within the IG kappa chains,
although the clusters generated shared
similarities to cluster formation at the
amino acid level, the two central cores
were completely distanced from each
other and, instead, a major cluster was
formed by four patients (P0103, P2451,
P3916 and P1939) (Figure 3B). Since these
four patients all carry a 10-amino acid
VK CDR3, the enhanced segregation of
clusters observed at the nucleotide level
is likely attributable to the additional
three nucleotides that these sequences
carry compared with cases carrying a 9-
amino acid VK CDR3; thus accounting
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Figure 1. Composite clusters of subset #4 IG sequences at the amino acid level. Figure 1A illustrates cluster formation following analysis of
the IGHV–IGHD–IGHJ amino acid sequences (n = 511). Six distinct clusters were observed: a central core was created by clonal se-
quences from two patients, P0103 and P2451, and from this core radiated a further five clusters. Figure 1B provides a more detailed view
of the composition of this central core. The central core is framed by dotted lines and each cluster is then dissected further. The seven se-
quences from P1422 segregated from the parent cluster were observed initially at diagnosis as a minor subclone, were represented by
only a single subcloned sequence at the second time point (1/33 subcloned sequences; 3%) and were undetectable at the third time
point. Figure 1C details cluster formation following analysis of the IGKV–IGKJ amino acid sequences (n = 397). Figure 1D provides a more
complete view of the major cluster resulting from analysis of the IGKV–IGKJ subclonal sequences. The major cluster is surrounded by dot-
ted lines, and a comprehensive breakdown of each cluster is provided. As observed with the IG heavy chain sequences, we noted that
individual IG kappa sequences occasionally were separated from their respective clusters, and instead attached to distant clusters. This
was particularly noted for three clonal sequences, one from P1939 and two from P2451, which carried 9-amino acid VK CDR3s while their
remaining clonal sequences all carried a 10-amino acid VK CDR3; the longer VK CDR3 is created by an additional proline at codon 115
and an equal proportion of subset #4 cases in this study carried either a 9-amino acid VK CDR3 or a 10-amino acid VK CDR3. During clus-
ter formation, patients with identical sequences become hidden by the last patient to be analyzed and found to harbor the exact same
sequence. Thus, while it may initially appear that P0907 is absent from the clustering analysis in Figure 1C, it is merely obscured by another
patient. This is illustrated in the reverse image of the P1939 (yellow)/P2920 (blue) cluster provided in Figure 1D, with the subclonal se-
quences of P0907 indicated by the red circle. Each circle represents subcloned sequences from one of the eight subset #4 patients in-
cluded in the study. Identical sequences overlap and are thus represented by a single circle. Circles are color coded to match the pa-
tient tag and different shades of the same color indicate subclonal sequences from the same patient but from a different time point. The
number within each circle indicates how many sequences carried that specific rearrangement. In Figure 1C, subcloned sequences with
a 9-amino acid VK CDR3 lie above the dashed gray line while subclonal sequences from patients with a 10-amino acid VK CDR3 lie
below the line. The number of circles appearing for each case is related to the level of intraclonal diversification observed. The asterisk
beside the number 42 in Figure 1B indicates that this circle represents sequences from more than one patient.
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for three additional sequence changes as
opposed to one at the amino acid level.
Taken collectively, this detailed com-
putational reconstruction of CLL subset
#4 clonal evolution based on merged IG
sequence data for all eight cases (at ei-
ther an amino acid or nucleotide level)
reveals a convergent and unified tumori-
genic evolutionary process. Thus, this
framework is indicative of a “consensus
path” of evolution for subset #4 cases
with the branched evolutionary growth
perhaps reflecting selective pressures
honing their BcR affinities.
Tracing the Origins of CLL Subset #4:
Molecular Phylogeny of CDR3
Sequences
Both the VH and VK CDR3s were vi-
sualized hierarchically with the aim of
constructing a CDR3 sequence at both
the nucleotide and amino acid level,
which then could be considered as the
root from which all subset #4 CDR3 se-
quences derive. Comparison of each
CDR3 sequence to the derived root se-
quence, using the same algorithmic pro-
cess applied throughout the entire vari-
able domain, enabled us to identify the
mutational path followed by each indi-
vidual patient.
With regards to the VH CDR3, the de-
rived root sequences for both nucleotide
and amino acids, were GCG AGA GGC
TAC GCG GAT ACA GCT GTG GTT AGG
AGG TAC TAC TAT TAC GGT ATG GAC
GTC and ARGYADTAVVRRYYYYGMDV,
respectively. These sequences would have
been created through the association of
the IGHV4-34 and IGHJ6 genes with the
IGHD5-18 gene in reading frame 1. Within
these sequence strings, GGC TAC GCG
(translation: GYA) and AGG AGG (trans-
lation: RR) cannot be assigned to the
germline sequence of any IGHD and/or
IGHJ gene, and thus would correspond to
nontemplated regions (N1 and N2, re-
spectively). Regarding the VK CDR3, the
derived root nucleotide and amino acid
sequences were ATG CAA GGC ACA
CAC TGG CCC CCG TAC ACT and
MQGTHWPPYT, respectively, and would
have been created by the association of
the IGKV2-30 and IGKJ2 genes.
Comparison of the complete VH CDR3
amino acid sequence data set to the root
revealed that no patient’s sequence ex-
actly matched the root. That said, clonal
sequences exhibiting the least differences
were from patients P1422, P1939, P2451
and P3916 while P0907, P2920 and P3020
were those located furthest away (Fig-
ure 4A). Within the VK CDR3 data set,
41% (162/397) of all kappa light chain se-
quences were identical to the derived
root. These sequences were from patients
P0103 (n = 75), P2451 (n = 60) and P3916
(n = 27), while their few remaining se-
quences together with the subclonal se-
quences obtained from all other patients,
contained only one or two differences,
thus explaining the limited branching
observed from the root (Figure 4B).
Overall, by adopting this strategy we
could for the first time propose the
A B 
Figure 2. Cluster formation when considering amino acids within the same physicochemical groups as equals. Figure 2A illustrates cluster-
ing of the IG heavy chains (n = 511) while figure 2B concerns clustering of the IG kappa light chains (n = 397). When considering amino
acids within the same physicochemical groups (as defined by IMGT) as equals, a new cluster was formed at the heavy chain level be-
tween P3020 and P0907 (previously represented by two distinct clusters) while the effect on IG kappa light chains was minor and pre-
dominantly related to the separation of P2920 and P0907 from the central cluster. Circles are color coded to match the patient tag and
different shades of the same color indicate subclonal sequences from the same patient but from a different time point. The number of
circles appearing for each case is related to the level of ID observed.
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preimmune VH and VK CDR3 which
forms the subset #4 BcR IG.
DISCUSSION
CLL subset #4 lies at the intersection
between autoimmunity and malignancy.
The expression of IGHV4-34 endows 
B cells with the capacity to recognize the
N-acetyllactosamine (NAL) antigenic epi-
tope present in both self and exogenous
antigens via a germline-encoded motif lo-
cated within the heavy variable frame-
work region 1 of the IGHV4-34 gene
(22,23). This motif remains intact in all
CLL subset #4 IG heavy chain sequences
despite a heavy SHM load and intense ID
(3,4,10). Notably, recombinant mono-
clonal antibodies from CLL subset #4 pa-
tients have been found to bind viable B
cells, recognizing the NAL epitope pres-
ent on B-cell CD45 (24,25). Additional
features encoded in the subset #4 IG BcR
sequence that hint at autoreactivity in-
clude: (i) the predicted high electroposi-
tivity of their long arginine-rich VH
CDR3s, reminiscent of pathogenic anti-
DNA antibodies; and (ii) the presence of
recurrent SHMs typified by the frequent
introduction of acidic residues, similar to
edited anti-DNA antibodies (3,9).
The route to malignancy for CLL sub-
set #4 clones may thus be a multifactor-
ial phenomenon, beginning with autore-
active precursors that undergo positive
selection by DNA, nucleosomes and/or
surface structures of apoptotic cells
(26,27). Thereafter, modifications intro-
duced by SHM may curtail this autore-
activity, thus rendering these clones an-
ergic (28–30), though still capable of
reactivation either through their BcRs
and/or other immune receptors, namely
toll-like receptors (TLRs) (31–35). While
this scenario bodes well for our under-
standing of the evolutionary pathway
followed by subset #4 clones, despite
much ingenuity and effort, our knowl-
edge about the specific eliciting anti-
gen(s) for subset #4 remains limited.
Along these lines, it is relevant to men-
tion that recombinant monoclonal anti-
bodies derived from subset #4 patients
lacked detectable reactivity with DNA,
however, upon removal of SHMs (rever-
sion to germline configuration), these
antibodies regained the ability to
strongly bind DNA (24). Nevertheless,
owing to difficulties in defining the un-
mutated progenitor rearrangement,
mainly due to the extensive SHM pres-
ent within subset #4 clones, the contribu-
tion made by the somatically generated
CDR3s to auto-antibody specificity
(24,25,36–39) may have been underesti-
mated, thus obscuring the actual anti-
body-antigen interactions (40–42).
In an attempt to clarify and enhance
our understanding of the ontogeny of











Figure 3. Composite clusters of subset #4 IG sequences at the nucleotide level. Figure 3A illustrates cluster formation following analysis of
the IGHV–IGHD–IGHJ nucleotide sequences (n = 511). Seven distinct clusters were observed; six clusters represented a single patient
each, while P0103 and P2451 remained clustered together, thus accounting for the seventh cluster. Figure 3B highlights cluster formation
following analysis of the IGKV–IGKJ nucleotide sequences (n = 397) and highlights the distancing of the two central cores and instead
the formation of a major cluster containing the subcloned sequences of four patients (P0103, P2451, P3916 and P1939). Circles are color
coded to match the patient tag and different shades of the same color indicate subclonal sequences from the same patient but from a
different time point. The number of circles appearing for each case is related to the level of intraclonal diversification observed.
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only to reconstruct the evolutionary his-
tory of subset #4 clones viewed as a
single antibody lineage, that is, the se-
quence of changes introduced into the
lineage during the development of the
clone, but also to identify the common
ancestral sequence from which all sub-
set #4 cases are derived—a task hitherto
unattainable due to the heavy SHM load
within the antigen-binding sites. One
means to obtain insight into the trajec-
tory of subset #4 clones would be
through characterization of their genetic
sequence, with the greatest insight ob-
tained from longitudinal sampling. Con-
sequently, for this purpose, we drew on a
community of related clones profiled at
different time points, for both heavy and
light chains, derived from 8 subset #4
cases (12). The Damerau–Levenshtein
distance algorithm, in the form of a
A 
B 
Figure 4. Molecular phylogeny of the VH and VK CDR3 sequences of subset #4. Figure 4A illustrates how hierarchical visualization of the
VH CDR3 amino acid sequence from all patients facilitated the construction of a VH CDR3 sequence that can now be considered as
the root from which all subset #4 VH CDR3 sequences are derived. Since no patient’s VH CDR3 sequence exactly matched the derived
root, they are visually placed as branches. Sequences that have an equal number of amino acid changes from the root are placed at
the same level (within the same row), since they branch from the root in a similar manner. Figure 4B illustrates the above phenomena for
the VK CDR3 amino acid sequences. The limited branching evidenced is indicative of sequence relatedness, with only one or two differ-
ences between any patient sequence and the derived root. Identical sequences overlap and are thus represented by a single circle.
The asterisk indicates that this circle represents sequences from more than one case. The number within each circle indicates how many
sequences carried that specific rearrangement.
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 purpose-built computational tool, was
applied and enabled us to infer both the
unmutated ancestral rearrangement and
the maturation intermediates, and hence
gain further insight into the interplay
between mutational constraints and se-
lection on antigen-binding affinity.
Through this approach the focused
evolution of subset #4, the evolution of
single entities into a community of re-
lated clones, was clearly evidenced with
most patient clusters found lying very
close to each other due to a high degree
of sequence relatedness. The branching
observed within such clusters could per-
haps reflect specific selective pressures
that occurred in parallel in distinct sub-
clones, as a means to fine-tune their BcR
affinities. Importantly, exploring the evo-
lutionary trajectory of subset #4 enabled
us to suggest for the first time the com-
mon ancestral sequence from which all
subset #4 cases likely descend. By deter-
mining the most probable sequence of
mutations, the mutationally preferred
pathway, the unmutated common ances-
tor (including the predicted VH CDR3)
could be inferred, which could now
serve as a template for antigen reactivity
studies (which should better predict anti-
gen specificities compared with previous
studies). Defining the antigens bound by
the CLL cells should aid in unraveling
the path to malignancy in subset #4. We
thus reason that knowledge of the subset
#4 ancestral rearrangement could pro-
vide a blueprint for the resolution of
crystal structures, which would not only
further define structural characteristics
of the #4 antibody, but also provide de-
tailed molecular insights into the nature
of contact sites between the antibody and
antigen.
CONCLUSION
The tale of CLL subset #4 is truly in-
triguing; bestowed with autoreactive
properties at birth, they fortuitously es-
cape immunological tolerance and exist
in an anergic state in the periphery, only
to reemerge as immunocompetent cells
(potentially due to dual engagement of
the BcRs and TLRs). That said, the story
is far from complete and unresolved is-
sues relate to where and under what in-
fluence SHM (and also switching to the
IgG isotype) occurs, and whether specific
modalities of BcR/TLR collaboration
and/or regulation may eventually im-
pact on the biological behavior of the
clones. Nevertheless, results from this
study unveil new leads in the ontogeny
of CLL subset #4 clones and bring fresh
insights, which may directly impact the
design of studies concerning the anti-
genic specificity of the clonotypic BcR
IGs. Although it is difficult to predict
how revelations in biological under-
standing may translate into improved
immunological interventions, it seems
reasonable to think that once a detailed
understanding of the B-cell ontogeny of
CLL subset #4 is achieved, doors for
therapeutic strategies may open, for ex-
ample, the design of peptides that would
inhibit or alter the consequences of anti-
gen-antibody interactions.
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